Uchida H

Department of Neuropsychiatry, Keio University School of Medicine (International College of Neuropsychopharmacology, CINP), Tokyo, Japan.

8 papers · ORCID

ArticleKetamine

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Uchida H, Gobbi G, Zohar J +7

Europe PMC2026
ArticleKetamine

Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial.

Nomoto K, Ohtani Y, Yatomi T +19

Europe PMC2026
ArticlePsilocybin

Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis.

Kishi T, Sakuma K, Hatano M +2

Europe PMC2026
ArticlePsilocybin

Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations.

Yonezawa K, Hirata M, Takano H +7

Europe PMC2026
ArticleKetamine

Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.

Ohtani Y, Tani H, Nomoto-Takahashi K +20

Europe PMC2024
ArticlePsychedelics

Development of the Japanese version of the Challenging Experience Questionnaire.

Tani H, Yonezawa K, Kusudo K +3

Europe PMC2024
ArticlePsychedelics

Development of the Japanese version of the 30-item Mystical Experience Questionnaire.

Yonezawa K, Tani H, Nakajima S +1

Europe PMC2024
ArticlePsilocybin

Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.

Sakurai H, Yonezawa K, Tani H +3

Europe PMC2022